RxDoctor Payments Data

Leann Vanduyn, NP

Family · Casa Grande, AZNPI 1235591546

Payments from drug & device makers

$430in general payments, 2019–2025

Across 22 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$122
  • AbbVie$113
  • Nestle Healthcare Nutrition Inc.$35
  • GSK$32
  • Grifols USA, LLC$30
  • Lilly USA, LLC$25
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$430 in reported general payments places this provider in the 50th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$33,357
Medicare patients
239
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$166,326
OzempicSemaglutide59$71,651
JardianceEmpagliflozin32$58,174
TrulicityDulaglutide29$57,416
XareltoRivaroxaban24$38,674
MounjaroTirzepatide21$29,125
EntrestoSacubitril/Valsartan15$24,247
Soliqua 100-33Insulin Glargine/Lixisenatide17$23,156
FarxigaDapagliflozin Propanediol20$15,055
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$9,846
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,236
Tresiba Flextouch U-100Insulin Degludec19$5,484
Atorvastatin Calcium666$5,229
Albuterol Sulfate HfaAlbuterol Sulfate126$4,925
Omeprazole274$4,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$25$86,54150 claims
Novo NordiskOzempic$15$71,65159 claims
NovartisEntresto$17$24,24715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,119 family providers in Arizona.

Other family in Casa Grande

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →